Conversely, treatment with anti-RANKL antibodies reversed the changes in the above indicators and aggravated lung tissue pathological damage in mice.<h4>Conclusion</h4>Pretreatment with recombinant RANKL can reduce lung damage in SA-ALI mice by inhibiting inflammation, with the underlying mechanism potentially associated with the OPG/RANKL/RANK/TLR4 pathway. This evidence concerns the gene TNFSF11 and acute respiratory distress syndrome.